Novo Nordisk Discontinues Once-Weekly Oral Semaglutide Development

On May 7, Novo Nordisk disclosed in its Q1 financial report that it has terminated the development of once-weekly oral semaglutide based on portfolio considerations.

Source: Novo Nordisk Official Website

Semaglutide, developed by Novo Nordisk, is a GLP-1R agonist. Its injectable form has been approved for the indications of type 2 diabetes, obesity, secondary prevention of cardiovascular events, and diabetic nephropathy. The once-daily oral formulation has been approved for type 2 diabetes, and the indications for obesity and MASH have already been submitted for marketing approval. (See:Heavyweight! Is the world's first oral weight-loss semaglutide really coming?）

Semaglutide This YearThe first quarter created$7.864 billion in sales, accounting for approximately 71% of Novo Nordisk's total revenue, was obtained in China.Approximately USD 318 million in revenue. (See:Novo Nordisk Q1 Earnings Report: "Semaglutide" Rakes in $7.864 Billion）

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent Moon

PR Article Coordination: WeChat insightxb